Bausch+Lomb Results Presentation Deck
Forward-Looking Statements
This presentation contains forward-looking information and statements, within the meaning of applicable securities laws (collectively, "forward-
looking statements"), including, but not limited to, statements regarding future prospects and performance of Bausch + Lomb Corporation
("Bausch + Lomb", the "Company", "we", "us", or "B+L") (including the Company's 2023 first quarter outlook and assumption thereof), the
planned spin-off or separation of the Company from Bausch Health Companies Inc. ("BHC") and the timing of the completion of such spin-off,
the anticipated opportunities of the Company as a standalone entity (including the potential for margin expansion, expected growth, the
durability of the markets in which we expect to grow, anticipated balance sheet flexibility and proposed use of same), the strength of resilience
of our product portfolio in connection with any potential recession and its ability to absorb slower consumer activity and continue growth, the
anticipated submission, approval and launch dates for certain of our pipeline products and R&D programs, the anticipated geographic
expansions and planned line extensions for certain of our products, the expected market acceptance for certain of our products and pipeline
products, the expected market size and compound annual growth rates for certain of the markets in which we have or expect to have products,
the timing of commencement and completion of clinical studies and other development work, anticipated effect of current market conditions and
recessionary pressures in one or more of our markets; the anticipated effect of macroeconomic factors, including inflation, the anticipated
impact of the COVID-19 pandemic on the Company and its financial condition, results of operation, revenues, segments, liquidity, products and
product pipeline, operations, facilities, supply chain and employees, Company's anticipated catalysts and business growth drivers, the
Company's strategic focus for 2023 and beyond, the Company's plans and expectations for 2023 and beyond and the anticipated timing in
which the Company will provide its 2023 guidance. Forward-looking statements may generally be identified by the use of the words
"anticipates," "expects," "predicts," "goals," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential,"
"target," "commit," "forecast," "tracking," or "continue" and positive and negative variations or similar expressions, and phrases or statements
that certain actions, events or results may, could, should or I be achieved, received or taken or will occur or result, and similar such
expressions also identify forward-looking information. These forward-looking statements, including the Company's 1Q23 outlook, are based
upon the current expectations and beliefs of management and are provided for the purpose of providing additional information about such
expectations and beliefs, and readers are cautioned that these statements may not be appropriate for other purposes. These forward-looking
statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-
looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties discussed in Bausch + Lomb's
filings with the U.S. Securities and Exchange Commission ("SEC") and the Canadian Securities Administrators (the "CSA") (including the
Company's Annual Report on Form 10-K for the year ended December 31, 2022 to be filed with the SEC on February 22, 2023 and its most
recent quarterly filings), which factors are incorporated herein by reference. They also include, but are not limited to, risks and uncertainties
relating to the proposed plan to spin off or separate the Company from Bausch Health, including the expected benefits and costs of the spin-off
transaction, the expected timing of completion of the spin-off transaction and its terms (including the expectation that the spin-off transaction
will be completed following the achievement of targeted net leverage ratios, subject to market conditions and receipt of applicable shareholder
and other necessary approvals), the ability to complete the spin-off transaction considering the various conditions to the completion of the spin-
off transaction (some of which are outside the Company's and BHC's control, including conditions related to regulatory matters and receipt of
applicable shareholder and other approvals), the impact of any potential sales of the Company's common shares by BHC that market or other
conditions are no longer favorable to completing the transaction, that applicable shareholder, stock exchange, regulatory or other approval is
not obtained on the terms or timelines anticipated or at all, business disruption during the pendency of or following the spin-off transaction,
diversion of management time on spin-off transaction-related issues, retention of existing management team members, the reaction of
customers and other parties to the spin-off transaction, the qualification of the spin-off transaction as a tax-free transaction for Canadian and/or
U.S. federal income tax purposes (including whether or not an advance ruling from the Canada Revenue Agency and/or the Internal Revenue
BAUSCH + LOMB
Service will be sought or obtained), the ability of the Company and BHC to satisfy the conditions required to maintain the tax-free status of the
spin-off transaction (some of which are beyond their control), other potential tax or other liabilities that may arise as a result of the spin-off
transaction, the potential dis-synergy costs resulting from the spin-off transaction, the impact of the spin-off transaction on relationships with
customers, suppliers, employees and other business counterparties, general economic conditions, conditions in the markets the Company is
engaged in, behavior of customers, suppliers and competitors, technological developments and legal and regulatory rules affecting the
Company's business. In particular, the Company can offer no assurance that any spin-off transaction will occur at all, or that any spin-off
transaction will occur on the terms and timelines anticipated by the Company and BHC. They also include, but are not limited to, risks and
uncertainties caused by or relating to the evolving COVID-19 pandemic, including potential effects and economic and future impact of that
pandemic (or resurgence thereof) and the reaction to it (including as it relates to the reinstitution of any lockdowns or other restrictions), all of
which are highly uncertain and cannot be predicted, and which may have a material adverse impact on the Company, including but not limited
to its supply chain, third-party suppliers, project development timelines, employee base, liquidity, stock price, financial condition and costs
(which may increase) and revenue and margins (both of which may decrease). Finally, they also include, but are not limited to, risks and
uncertainties caused by or relating to a potential recession and other adverse economic conditions (such as inflation and slower growth), which
could adversely impact our revenues, expenses and resulting margins and economic factors over which we have no control, including
inflationary pressures as a result of historically high domestic and global inflation and otherwise, interest rates, foreign currency rates, and the
positional effect of such factors on revenues, expenses and resulting margins. In addition, certain material factors and assumptions have been
applied in making these forward-looking statements, including, without limitation, assumptions regarding our 1Q23 outlook with respect to
expectations regarding growth in the overall eyecare market, currency headwinds, the pace of recovery in China, carryover leading to gross
margin pressure, exchange rates and the higher cost of inventory; and the assumption that the risks and uncertainties outlined above will not
cause actual results or events to differ materially from those described in these forward-looking statements. Management has also made
certain assumptions in assessing the anticipated impacts of the COVID-19 pandemic on the Company and its results of operations and
financial conditions, including: that there will be no material restrictions on access to health care products and services resulting from a possible
resurgence of the virus and variant and subvariant strains thereof on a global basis in 2023; there will be increased availability and use of
effective vaccines; that the strict social restrictions in the first half of 2020 will not be materially re-enacted in the event of a material resurgence
of the virus and variant and subvariant strains thereof; that there will be an ongoing, gradual global recovery as the macroeconomic and health
care impacts of the COVID-19 pandemic diminish over time; that the largest impact to the Company's businesses were seen in the second
quarter of 2020; that, while our revenues have returned to pre-pandemic levels for many of our businesses and geographies, the rates of
recovery for each business will vary by geography with some regions, including China, continuing to experience negative impacts of the
COVID-19 pandemic on our business in those regions; and no major interruptions in the Company's supply chain and distribution channels. If
any of these assumptions regarding the impacts of the COVID-19 pandemic are incorrect, our actual results could differ materially from those
described in these forward-looking statements.
Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only
as of the date hereof. Bausch + Lomb undertakes no obligation to update any of these forward-looking statements to reflect events or
circumstances after the date of this presentation or to reflect actual outcomes, unless required by law.
The outlook in this presentation is only effective as of the date given, Feb. 22, 2023. Distribution or reference of this deck following Feb. 22,
2023 does not constitute the Company updating outlook.
1View entire presentation